Nitrosamine impurities have become a concern in the bio/pharmaceutical industries, due to their carcinogenic properties and presence in medications.
Nitrosamine impurities have become a concern in the bio/pharmaceutical industries, due to their carcinogenic properties and presence in medications. In response to this issue, we have developed a range of services to help identify and mitigate nitrosamine impurities in drug products. In a recent webinar addressing the bio/pharmaceutical sectors, SGS experts discussed identifying and managing nitrosamine impurities in bio/pharmaceutical products.
Download Now
Asset 5: Navigating nitrosamine impurity testing
PDF, Size 0 kb
Topics
- AI, analytics and decision support
- Analytical and bioanalysis
- Bioprocessing and biomanufacturing
- Chromatography and separations
- Controlled release and advanced delivery
- Drug Development
- Endotoxin
- Formulation and drug delivery
- GMP and quality management systems (QMS)
- Quality, microbiology and contamination control
- Regulation and compliance
- SGS Life Sciences
- Upstream processing
